Any significant acute or chronic medical illness
Other acute or chronic medical or psychiatric condition
Acute or chronic liver or renal disease
Acute or chronic medical or psychological illnesses that prevent endoscopy procedures
Acute or chronic skin and/or microvascular disorders
Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollment
Documented malabsorptive syndromes including enteropathies, gastroenteritis (acute or chronic) or diarrhea (acute or chronic)
Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded
Other severe acute or chronic medical condition
Systemic rheumatic or autoimmune diseases or acute or chronic infections
Acute VOC ending 7 days prior to first dosing
Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
Patients must not have received any prior systemic therapy for ALL, except for the acute management of hyperleukocytosis or acute symptoms (e.g., corticosteroids, cytarabine, etc.)
Be undergoing treatment for acute or chronic hepatitis C.
Acute or chronic pancreatic disease within the last year prior to enrollment
Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
Acute or chronic skin disorders that would interfere with subcutaneous injection of the vaccine or subsequent assessment of potential skin reactions
Acute, severe infection (e.g., sepsis and opportunistic infections), or active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., herpes zoster).
Any acute or chronic psychiatric problems
Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollment
Subjects with any acute infection or severe or uncontrolled that requires systematic antibiotic therapy; acute therapy must have been completed at least seven days prior to study enrollment
Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded
Acute or sub-acute intestinal obstruction
Evidence of active acute or chronic infection
Ongoing acute or chronic inflammatory skin disease.
Chronic immunosuppression
Acute or chronic pancreatic disease
Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
Be undergoing treatment for acute or chronic hepatitis C.
Prostate abscess, chronic or acute prostatitis, or neurogenic bladder
Patients with acute myelofibrosis are excluded
Significant acute or chronic infections
Have malabsorptive syndromes, enteropathies, gastroenteritis (acute or chronic), or diarrhea (acute or chronic).
Acute or chronic liver, pancreatic or severe renal disease
Ongoing acute or chronic inflammatory skin disease.
Acute or chronic pancreatic disease
Acute or chronic liver or severe renal disease
Active (acute or chronic) or uncontrolled severe infections (not responding to antibiotics), including acute pelvic inflammatory disease
Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded
Acute or chronic pancreatic disease
Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
Active (acute or chronic) or uncontrolled severe infection
Acute or chronic liver or pancreatic disease.
Acute or chronic pancreatic disease
Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
Acute or chronic pancreatic disease
Acute or chronic liver disease or severe renal disease considered unrelated to the cancer
No evidence of acute infection
Significant acute or chronic infections, including:
Acute or chronic medical or psychological illnesses that prevent endoscopy procedures
Patients with acute or chronic infection
Ongoing acute or chronic inflammatory skin disease.
Procedures that occur during acute hospitalization.
Acute nephritis
Has an Acute Physiology and Chronic Health Evaluation (APACHE) II score < 10
Skin toxicity including but not limited to erythema, rash, ulceration, and open wound that is still clinically present and considered as acute or chronic.
Acute or chronic skin disorders that will interfere with subcutaneous injection of the vaccine or subsequent assessment of potential skin reactions
Have a chronic underlying infection
Significant acute or chronic medical illness.
History of functionally limiting chronic or acute cardiac, pulmonary, or neuromuscular disease
Sepsis and/or acute, chronic, or ongoing infections that are currently being treated with systemic antimicrobials
Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
Acute suicidal behavior.
Acute medical conditions, such as acute flare-up of joint condition or infection
Acute abdomen
Known chronic aspiration
Chronic immunosuppression
Acute or chronic respiratory disease
Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency
acute respiratory failure,
acute myocarditis or
acute systemic infection and
Acute prostatitis within the last 6 months
Patients suffering from active acute or chronic prostatitis
Have an acute or a chronic hematoma and/or acute ecchymosis of the thyroid;
Symptomatic acute prostatitis
AND with one or more of the following highly prevalent ambulatory-sensitive chronic conditions (diabetes, hypertension, chronic lung disease, chronic kidney disease, depression, or heart disease).
Not in acute crisis
